New Preclinical Research Evaluating Cellular Reprogramming for Age Reversal

Written By Noah Davidsohn

Rejuvenate Bio announced new preclinical research published to the preprint server bioRxiv that evaluates how partial reprogramming could be a potential treatment in the elderly to reverse age-associated diseases and potentially extend human lifespan.

Noah Davidsohn
Previous

Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy
Next

Rejuvenate Bio Appoints Deborah Ascheim, M.D., as Chief Medical Officer